Analysis of Coexisting Gene with NRAS in Acute Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2022.02.005
- Author:
Ye-Ping SHENG
1
;
Hai-Ying HUA
2
;
Hong-Ying CHAO
3
;
Wen-Yan ZHU
4
;
Zhi-Qing WANG
4
;
Yan ZHANG
4
;
Ye ZHOU
4
Author Information
1. Department of Hematology, Affiliated Hospital of Jiangnan University, Wuxi 214000, Jiangsu Province, China,Nantong University of Medicine, Nantong 226001, Jiangsu Province, China.
2. Department of Hematology, Affiliated Hospital of Jiangnan University, Wuxi 214000, Jiangsu Province, China,E-mail:huahy007@163.com.
3. Department of Hematology, Changzhou Second Hospital, Changzhou 213003, Jiangsu Province, China.
4. Department of Hematology, Affiliated Hospital of Jiangnan University, Wuxi 214000, Jiangsu Province, China.
- Publication Type:Journal Article
- Keywords:
NRAS;
acute myeloid leukemia;
gene mutation
- MeSH:
Core Binding Factor Alpha 2 Subunit/genetics*;
GTP Phosphohydrolases/genetics*;
Humans;
Leukemia, Myeloid, Acute/genetics*;
Membrane Proteins/genetics*;
Mutation;
Nucleophosmin;
Prognosis;
Proto-Oncogene Proteins p21(ras)/genetics*;
fms-Like Tyrosine Kinase 3
- From:
Journal of Experimental Hematology
2022;30(2):351-356
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the coexisting mutations and clinical significance of Homo sapiens neuroblastoma RAS viral oncogene homolog (NRAS) gene in acute myeloid leukemia (AML) patients.
METHODS:High-throughput DNA sequencing and Sanger sequencing were used to detect 51 gene mutations. The occurrence, clinical characteristics and treatment efficacy of coexisting genes with NRAS were investigated.
RESULTS:A total of 57 NRAS mutations (17.5%) were detected in 326 patients with AML. Compared with the patients in NRAS non-mutation group, patients in the mutant group were younger (P=0.018) and showed lower platelet count (P=0.033), but there was no significant difference in peripheral leukocyte count, hemoglobin, and sex. For FAB classification, NRAS mutation and M2 subtype showed mutually exclusive (P=0.038). Among 57 patients carried with NRAS mutation, 51 (89.5%) patients carried with other gene mutations, 25 (43.9%) carried with double gene mutations, 10 (17.5%) carried with 3 gene mutations, and 16 (28.1%) corried with ≥ 4 gene mutations. The most common coexisting gene mutation was KRAS (24.6%, 14/57), followed by FLT3-ITD (14.0%, 8/57), RUNX1 (12.3%, 7/57), NPM1 (10.5%, 6/57), PTPN11 (10.5%, 6/57), DNMT3A (10.5%, 6/57) and so on. The age (P=0.013, P=0.005) and peripheral platelet count (P=0.007, P=0.021) of patients with NPM1 or DNMT3A mutations were higher than those of the patients with wild type, but there was no significant difference in peripheral leukocyte count and hemoglobin. Also, there was no significant difference in age, peripheral leukocyte count, hemoglobin, and peripheral platelet count between the patients in KRAS, FLT3-ITD, RUNX1 or PTPN11 mutant group and the wild group. Patients with FLT3-ITD mutations showed a lower complete remission (CR) rate (P=0.044). However, there was no significant difference in CR rate between the patients with KRAS, NPM1, RUNX1, PTPN11 or DNMT3A mutations and the wild group. The CR rate of the patents with single gene mutation, double gene mutations, 3 gene mutations, and≥ 4 gene mutations were decreased gradually, and there was no significant difference in CR rate between pairwise comparisons.
CONCLUSION:The mutation rate of NRAS mutation is 17.5%, 89.5% of AML patients with NRAS mutation coexist with additional gene mutations. The type of coexisting mutations has a certain impact on clinical characteristics and CR rate of patients with AML.
